Literature DB >> 16938573

6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance.

Roelandt F J Schop1, Scott A Van Wier, Ruifang Xu, Irene Ghobrial, Gregory J Ahmann, Philip R Greipp, Robert A Kyle, Angela Dispenzieri, Martha Q Lacy, S Vincent Rajkumar, Morie A Gertz, Rafael Fonseca.   

Abstract

IgM monoclonal gammopathy of undetermined significance (IgM MGUS) and Waldenström macroglobulinemia (WM) are sometimes clinically difficult to distinguish. In our previous study, deletion of the long arm of chromosome 6 (6q) was found in about half of WM patients. To further clarify the area of minimal deletion at 6q (6q-) and to address the issue of whether 6q- occurs in IgM MGUS, 12 IgM MGUS and 38 WM patients were studied by fluorescence in situ hybridization using probes targeting different chromosomal segments of 6q. No 6q deletions were found in IgM MGUS samples. Of 38 successfully studied WM patients, 21 (55%) showed a deletion of 6q. The area of minimal deletion was between 6q23 and 6q24.3, but the deletion usually encompassed a large fragment of the 6q arm. These results indicate that 6q- can distinguish WM from IgM MGUS and is likely to be a secondary event.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16938573     DOI: 10.1016/j.cancergencyto.2006.04.009

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  23 in total

1.  IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia.

Authors:  Steven R Schuster; Sundararajan Vincent Rajkumar; Angela Dispenzieri; William Morice; Alvaro Moreno Aspitia; Stephen Ansell; Robert Kyle; Joseph Mikhael
Journal:  Am J Hematol       Date:  2010-11       Impact factor: 10.047

Review 2.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

3.  Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1.

Authors:  Kasyapa S Chitta; Aneel Paulus; Sikander Ailawadhi; Barbara A Foster; Michael T Moser; Petr Starostik; Aisha Masood; Taimur Sher; Kena C Miller; Dan M Iancu; Jeffrey Conroy; Norma J Nowak; Sheila N Sait; David A Personett; Morton Coleman; Richard R Furman; Peter Martin; Stephen M Ansell; Kelvin Lee; Asher A Chanan-Khan
Journal:  Leuk Lymphoma       Date:  2012-08-27

4.  Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.

Authors:  B Paiva; M C Montes; R García-Sanz; E M Ocio; J Alonso; N de Las Heras; F Escalante; R Cuello; A G de Coca; J Galende; J Hernández; M Sierra; A Martin; E Pardal; A Bárez; J Alonso; L Suarez; T J González-López; J J Perez; A Orfao; M-B Vidríales; J F San Miguel
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528

5.  Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

Authors:  Zachary R Hunter; Lian Xu; Guang Yang; Nicholas Tsakmaklis; Josephine M Vos; Xia Liu; Jie Chen; Robert J Manning; Jiaji G Chen; Philip Brodsky; Christopher J Patterson; Joshua Gustine; Toni Dubeau; Jorge J Castillo; Kenneth C Anderson; Nikhil M Munshi; Steven P Treon
Journal:  Blood       Date:  2016-06-14       Impact factor: 22.113

Review 6.  Genetic factors and pathogenesis of Waldenström's macroglobulinemia.

Authors:  Jorge Monge; Esteban Braggio; Stephen M Ansell
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 7.  Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.

Authors:  Stephen M Ansell; Robert A Kyle; Craig B Reeder; Rafael Fonseca; Joseph R Mikhael; William G Morice; P Leif Bergsagel; Francis K Buadi; Joseph P Colgan; David Dingli; Angela Dispenzieri; Philip R Greipp; Thomas M Habermann; Suzanne R Hayman; David J Inwards; Patrick B Johnston; Shaji K Kumar; Martha Q Lacy; John A Lust; Svetomir N Markovic; Ivana N M Micallef; Grzegorz S Nowakowski; Luis F Porrata; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Carrie A Thompson; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; Morie A Gertz
Journal:  Mayo Clin Proc       Date:  2010-08-11       Impact factor: 7.616

8.  Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.

Authors:  Florence Nguyen-Khac; Jerome Lambert; Elise Chapiro; Aurore Grelier; Sarah Mould; Carole Barin; Agnes Daudignon; Nathalie Gachard; Stéphanie Struski; Catherine Henry; Dominique Penther; Hossein Mossafa; Joris Andrieux; Virginie Eclache; Chrystèle Bilhou-Nabera; Isabelle Luquet; Christine Terre; Laurence Baranger; Francine Mugneret; Jean Chiesa; Marie-Joelle Mozziconacci; Evelyne Callet-Bauchu; Lauren Veronese; Hélène Blons; Roger Owen; Julie Lejeune; Sylvie Chevret; Hélène Merle-Beral; Véronique Leblondon
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 9.  Update on therapeutic options in Waldenström macroglobulinemia.

Authors:  Xavier Leleu; Julie Gay; Aldo M Roccaro; Anne-Sophie Moreau; Stephanie Poulain; Remy Dulery; Berenice Bro Des Champs; Daniela Robu; Irene M Ghobrial
Journal:  Eur J Haematol       Date:  2009-01       Impact factor: 2.997

10.  High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas.

Authors:  Esteban Braggio; Jonathan J Keats; Xavier Leleu; Scott Van Wier; Victor Hugo Jimenez-Zepeda; Roelandt F J Schop; Marta Chesi; Michael Barrett; Alexander Keith Stewart; Ahmet Dogan; Peter Leif Bergsagel; Irene M Ghobrial; Rafael Fonseca
Journal:  Clin Lymphoma Myeloma       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.